This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Genomic sequencing is a window into our genetic makeup. The GUARDIAN (Genomic Uniform-screening Against Rare Diseases In All Newborns) study, recently published in the Journal of the American Medical Association (JAMA) , highlights how adding genome sequencing to newborn screening could reshape early detection for rare genetic conditions.
The Abu Dhabi Department of Health (DoH) in the UAE has made a declaration of collaboration with Mass General Brigham’s (MGB) International Center for Genetic Disease (iCGD) to advance lifesciences.
The field of genomic medicine has reached a true turning point. More efficient, suspension-based cell culture processes are urgently needed in the now fast-developing genomic medicine space. Cytiva and the Drop logo are trademarks of LifeSciences IP Holdings Corp. CEVEC became part of Cytiva in October 2022.
GSK has entered a strategic partnership with Wave LifeSciences to progress the discovery and development of oligonucleotide therapies for new genetic targets. The alliance will merge the PRISM oligonucleotide platform of Wave and the capabilities of GSK in genetics and genomics.
From the Human Genome Project to contemporary drug development, collaboration is critical to the lifesciences. It is also an important factor in the success of lifesciences clusters, where a high concentration of pharmaceutical or medical device companies can all be found in one district, city or region.
Canary Wharf’s bid to become a new hub for the lifesciences sector in the UK has been given a boost following the decision by Genomics England to relocate to the development. facility dedicated to a combination of wet lab and office space, revealed in March, intended as a focal point for lifesciences companies in London.
Lifescience podcasts have emerged as an invaluable tool for building connections with audiences in the digital era. Furthermore, we’ll explore the unique advertising opportunities that this platform offers, positioning brands at the forefront of the lifescience industry. The result?
If the power of the lifesciences industry to innovate and collaborate were ever in doubt, the speed at which vaccines for COVID-19 were discovered, developed, trialled, approved and manufactured have confirmed just how dynamic the industry can be. Building the data-powered lifesciences business .
Xtalks is proud to announce the launch of the Xtalks LifeScience podcast. Subscribe to the Xtalks LifeScience Podcast to never miss a new episode. Fresh Conversations About LifeScience Topics. She focuses on news relating to the food industry and writes blogs on recruitment and HR in the lifesciences.
As we step into 2024, the lifesciences continue to evolve at an unprecedented pace, driven by technological innovation, a deeper understanding of human biology and the application of new technologies in areas like drug development and health wearables. These companies are at various stages of research and clinical trials.
On International Women’s Day, Xtalks is celebrating women’s leadership in the lifesciences by highlighting some of the female leaders at the forefront of scientific discovery, as well as the continuing challenges of attaining more equitable representation. Challenges in Women’s Leadership.
The application of whole genome sequencing (WGS) to derive a more complete understanding of cancer has been a central goal of cancer researchers even before the first human genome was decoded in 2003. Ultima Genomics has already partnered with other leading biotech startups.
How did you get into lifesciences? After a few years, I decided I wanted to move into the commercial side of the business, so I completed an MBA and went on to hold various positions in Corporate Business Development, LifeScience and Healthcare. What has your career path been? Ultimately, this has to start at school.
Subscribe to the Xtalks LifeScience Podcast to never miss a new episode. It leverages various patient-specific factors, including genetics, age, weight, organ function and even lifestyle, to determine the most appropriate dosage for each individual.
– A Purdue Foundry-affiliated company with a growing reputation as a search engine for genome sequence data in lifesciences has joined a nationally ranked health care startup accelerator. Credit: Karyosoft/Rajesh Perianayagam WEST LAFAYETTE, Ind.
David Del Bourgo (CEO and co-founder, Whitelab Genomics) has always been passionate about introducing disruptive, innovative technologies to markets. We founded Whitelab Genomics after realising the potential to use data, data science, and AI in a more systematic way to develop genomic therapies,” Del Bourgo says.
27, Vilnius will host the EFIB’2022 event which will bring the European lifescience sector together. In the field of lifesciences, Lithuania is best known for the discovery of gene scissors by Prof. Lab, focused on research and development of novel genome editing tools. Virginijus Šikšnys.
Alongside drugs and therapeutics, data collection and technology enhancements have redefined the traditional healthcare experience, especially within oncology, and genomic profiling has become a significant factor in allowing for personalised care. The post The use of genomic profiling testing to improve oncology care appeared first on.
This episode features an interview with Dr. Asaf Zviran, CEO and co-founder of C2i Genomics, a biotech company focused on improving cancer detection and monitoring using genomics- and AI-based approaches. Zviran’s founded C2i Genomics, including a personal story, and how the company is focused on truly personalizing cancer treatments.
With the huge abundance of genomic data generated from lifescience experiments, processing large datasets remains a challenge in the field of bioinformatics.
Xtalks is taking a look at some of the major stories and innovations of the year in the lifesciences, many of which were driven by new, emerging and improved technologies. The year 2021 was all about continuing innovations in the lifesciences. LifeScience Innovations: Malaria and Influenza Vaccines.
ERS Genomics and G+FLAS LifeSciences sign CRISPR/Cas9 license agreement ERS Genomics and G+FLAS LifeSciences sign CRISPR/Cas9 license agreement G+FLAS LifeSciences is applying CRISPR technology to develop research tools and reagents DUBLIN & SEOUL–(BUSINESS WIRE)–ERS Genomics Limited, which … Continue reading →
Biopharma and lifesciences companies from across the globe provide updates on their pipelines and business operations including Takeda, Origin Therapeutics, ERS Genomics and more.
The UK’s long-awaited LifeSciences Vision strategy has been published, setting out the government’s stall as it tries to deliver on its promise to keep the country at the forefront of the sector. ” The post Dementia, cancer headline UK’s 10-year plan for lifesciences sector appeared first on.
For more information on tackling this “genomic analysis bottleneck,” watch this on-demand webinar. HS: Due to the heterogeneity of the rare disease population, there are many relevant gene lists, and the genomic data analysis of these patients covers almost 2,000 different genetic targets.
Nashville Biosciences and Illumina Announce Agreement to Establish Preeminent Clinico-Genomic Resource for LifeSciences Research & Development Nashville Biosciences and Illumina Announce Agreement to Establish Preeminent Clinico-Genomic Resource for LifeSciences Research & Development NASHVILLE, Tenn.–(BUSINESS
The PING Conference 2022 is back in person this year, with opportunities to network face-to-face with people from right across the lifesciences ecosystem. Hear about how the UK is leading the way in what has been described as the ‘Golden Age for LifeSciences Innovation’ and the opportunities arising from this from leading experts.
With the latest advances in whole genome sequencing , it is increasingly clear that rare epilepsies are largely caused by a single genomic mutation, says Ferraro. New developments in the anti-seizure pipeline Genomic screenings can also be used to sharpen the efficacy of already available treatments.
Illumina, the world’s leading DNA sequencing and array-based technologies company, is partnering with Sequoia Capital China, an investment firm, to launch a lifesciences incubator in China. It is dubbed the Sequoia Capital China Intelligent Healthcare Genomics Incubator, Powered by Illumina.
The ABPI’ s chief executive Dr Richard Torbett outlines a new ‘vision’ and 10-year strategy for UK lifesciences, launched by the government today. After an extraordinary year of science versus disease, the UK has cemented itself at the forefront of the global response to COVID-19.
Illumina , the world’s leading DNA sequencing and array-based technologies company, is partnering with Sequoia Capital China, an investment firm, to launch a lifesciences incubator in China. It is dubbed the Sequoia Capital China Intelligent Healthcare Genomics Incubator, Powered by Illumina.
BARCELONA/LONDON, 25.05.23: Seqera Labs, the leading provider of secure workflow orchestration software in the lifesciences sector, has partnered with Genomics England, the government-owned company that launched the 100,000 Genomes Project in partnership with the NHS.
It’s time to take what the UK has learnt about the “Holy Trinity” of government, academia, and industry and apply it to creating a “lifesciences superpower”, says health secretary Matt Hancock. It’s about charting a new, better course… and transforming the UK into a lifesciences superpower.
This year’s top 30 large and small companies operate in some of the LifeSciences’ hottest spaces – precision medicine, vaccines, gene editing, genomics and oncology.
Sek Kathiresan, cardiologist and CEO of Verve Therapeutics, joins us to explain the company’s work on preventing heart disease with genome editing. We also break down the latest news in the lifesciences, including a long-awaited victory for Novavax and ostensible good news for biotech.
AAV genomes are highly compact, with overlapping coding regions, alternate splicing schemes, and multiple transcription initiation codons. There are two main genes in the AAV genome, rep and cap, which encode nine different proteins.
This involves the integrated analysis of several layers of biological data, including genomic, proteomic, transcriptomic and phosphoproteomic data using novel transomics technologies involving lab methods and AI approaches. Subscribe to the Xtalks LifeScience Podcast to never miss a new episode.
Our colleague Matthew Herper joins us for a deep dive into Illumina, explaining how the biggest company in genome sequencing lost the faith of shareholders and painted itself into a corner.
(NASDAQ: ILMN), the global leader in DNA sequencing and array-based technologies, and Sequoia Capital China , a leading investment firm, today announced a collaboration to catalyze the startup ecosystem in China with the launch of the Sequoia Capital China Intelligent Healthcare Genomics Incubator, Powered by Illumina.
John Finn, PhD Chief Scientific Officer Tome Biosciences Dr. Finn has over 20 years of experience in the gene therapy space with a focus on genome editing and delivery technologies. Subscribe to the Xtalks LifeScience Podcast to never miss a new episode.
Lee Honigberg on the Future of Blood-Based Biomarker Assays GeneDX GeneDX recently integrated AI (Multiscore) into its interpretation platform, improving speed and accuracy in analyzing complex genomic data. 10x Genomics 10x Genomics reported $707 million in 2024 revenue.
The up-and-coming field of spatial genomics in biology promises to bridge the gap between high plex, high throughput, and high resolution. 70+ spatial Genomics solutions are developed by industry and non-industry players. 70+ spatial Genomics solutions are developed by industry and non-industry players. Concluding Remarks.
27, Vilnius will host the EFIB’2022 event which will bring the European lifescience sector together. In the field of lifesciences, Lithuania is best known for the discovery of gene scissors by Prof. Lab, focused on research and development of novel genome editing tools. Virginijus Šikšnys.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content